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Abstract
Background: Maintenance of therapeutic International Normalized Ratio (INR) in the community
is generally poor. The supervised environment in long-term care facilities may represent a more
ideal setting for warfarin therapy since laboratory monitoring, compliance, dose adjustment, and
interacting medications can all be monitored and controlled. The objectives of this study were to
determine how effectively warfarin was administered to a cohort of residents in long-term care
facilities, to identify the proportion of residents prescribed warfarin-interacting drugs and to
ascertain factors associated with poor INR control.
Methods: A chart review of 105 residents receiving warfarin therapy in five long-term care
facilities in Hamilton, Ontario was performed. Data were collected on INR levels, warfarin
prescribing and monitoring practices, and use of interacting medications.
Results: Over a 12 month period (28,555 resident-days, 78.2 resident years) 3065 INR values
were available. Residents were within, below and above the therapeutic range 54%, 35% and 11%
of the time, respectively. Seventy-nine percent of residents were prescribed at least one warfarin-
interacting medication during the period in review. Residents receiving interacting medications
spent less time in the therapeutic range (53.0% vs. 58.2%, OR = 0.93, 95% confidence interval 0.88
to 0.97, P = 0.002). Adequacy of anticoagulation varied significantly between physicians (time in
therapeutic range 45.9 to 63.9%).
Conclusion: In this group of long-term care residents, warfarin control was suboptimal. Both
prescriber and co-prescription of interacting medications were associated with poorer INR
control. Future studies should seek strategies to improve prescriber skill and decrease use of
interacting medications.
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Background
Warfarin is frequently prescribed to the elderly; often for
primary or secondary prevention of stroke in patients with
atrial fibrillation [1] or to prevent recurrent venous
thromboembolism (VTE) [2] Residents of long-term care
(LTC) facilities are particularly likely to receive warfarin
given the high prevalence of atrial fibrillation [3,4] and
incidence of VTE [5] in this older population.
Although good quality evidence suggests an optimal tar-
get International Normalized Ratio (INR) of 2.0–3.0 for
these common indications [6-8], maintenance of thera-
peutic INR in the community is generally poor [9-11].
LTC facilities may represent ideal environments for warfa-
rin therapy since laboratory monitoring, compliance,
dose adjustment, and interacting medications can all be
monitored and controlled.
Despite the frequency of warfarin use in LTC and the
unique care environment, relatively few studies have
examined how well warfarin therapy is provided to resi-
dents of LTC facilities. We sought to address this knowl-
edge deficit by performing a retrospective chart review.
Our objectives were to determine: (1) the percentage of
time residents spent in the therapeutic international nor-
malized ratio (INR) range, (2) the prevalence and inci-
dence of prescription of warfarin-interacting drugs and
(3) whether co-prescription of medications known to
interact with warfarin was associated with the proportion
of time in the therapeutic range.
Methods
Setting and patients
The study sample consisted of all residents at five LTC
facilities in Hamilton, Ontario. The facilities had a total of
1144 residents (mean 229 residents). These facilities pro-
vide nursing care and residential facilities for individuals
no longer able to live in the community; each facility pro-
vides medication dispensing and laboratory monitoring
services in addition to assistance with activities of daily
living. All prescription medications received by residents
are dispensed by a single pharmacy providing service to
that facility.
Study design
Residents were identified from the centralized pharmacy
database for the LTC facilities. The retrospective chart
review included data from the preceding twelve months.
Using a standardized form, two reviewers (MV and BM)
abstracted data from facility charts for each resident
receiving warfarin for the period between October 2004
and April 2005. Information collected included: indica-
tion for anticoagulation, INR results, target range, and
INR-testing intervals. In addition demographic data for
each participant, including age, sex, comorbidities, con-
comitant medications and prescribing physician was
recorded for statistical analysis.
To identify prescription of medications known to interact
with warfarin, we compiled a list based on "highly proba-
ble" and "probable" interactions in a recent systematic
review, [12] and cross-referenced it with the pharmacy
database for our sample population. Initiation or change
in dose of medications known to interact with warfarin
was also recorded.
Statistical analysis
Analysis of quantitative (including descriptive statistics)
and qualitative data was conducted. In the primary analy-
sis we assessed quality of treatment based on TTR (thera-
peutic range = 2.0–3.0). Linear interpolation of INR, in
the method of Rosendaal et.al. [13], was used to character-
ize each day of warfarin therapy: INR values were assigned
to each day between INR measurements based on a postu-
lated linear change. Values were rounded to one decimal
place. Mantel-Haenszel weighted odds ratios (OR's) and
95% CI's were computed where appropriate (EpiInfo,
Centers for Disease Control, Atlanta, Georgia, 2004). The
association between baseline and time dependent factors
and adequacy of anticoagulation was to be queried using
univariable analysis. Multivariable analysis proved to not
be possible because of strong interaction between base-
line and time dependent variables.
Ethics
Before proceeding with data collection, approval was
obtained from the Medical Director, Administrator, and
Director of Care at each facility. Consent was not obtained
from individual residents. Each resident was assigned a
numerical code which was used on all study documents to
prevent identification of their personal information. The
facility's Professional Advisory Committee reviewed the
protocol. Approval for this project was received from the
Research Ethics Board at McMaster University.
Results
Sample demographics
Overall, 107 of 1144 (9%, 95% CI 8% to 11%) residents
were prescribed warfarin. Residents prescribed warfarin
were predominantly female (72%), with a mean age of
83.6 years (range 54.7–98.0). All but two of the residents
were over the age of 65. Two residents had medical indi-
cations for target INR above 2.0–3.0 and were thus
excluded from the analysis. Depending on length of stay
at the LTC facilities and duration of anticoagulation with
warfarin, the duration of the audit for individual residents
ranged from 0.7 to 13.3 months (mean 9.1).
The majority of residents in our sample had atrial fibrilla-
tion (67%), or a history of stroke or transient ischemicBMC Geriatrics 2008, 8:13 http://www.biomedcentral.com/1471-2318/8/13
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attack (53%). A large proportion had hypertension
(50%), coronary artery disease (48%), dementia (37%),
osteoarthritis (31%), congestive heart failure (31%) or
diabetes mellitus (22%). The percentage of residents with
depression, chronic obstructive pulmonary disease, oste-
oporosis, asthma, anemia, renal impairment and history
of cancer was 18%, 14%, 14%, 10%, 8%, 6% and 20%
respectively. The most common indications for warfarin
were stroke prophylaxis in atrial fibrillation (67%) and
treatment of deep vein thrombosis (18%) (Figure 1). In 9
of the 105 residents (9%) the indication for anticoagula-
tion with warfarin was not clear after complete review of
the facility chart, though the stated target INR was 2.0–
3.0. Ten residents had two documented indications for
warfarin therapy.
INR
Over the period of the chart review, a total of 3065 INR
values were available, representing 28,555 resident days
(78.2 resident years). The average number of INR meas-
urements per resident was 3.4 per month (average of one
measurement every 9 days). Linear interpolation of INR
values [13] was performed to assign an INR value to each
patient day. Overall, residents spent 54.1% of time in the
therapeutic range (INR 2.0–3.0). Residents' anticoagula-
tion was subtherapeutic (<2.0) 34.7% of the time and
supratherapeutic (>3.0) 11.2% of the time. We further
broke down the data into ranges and found that a large
proportion of the time (27.7%) was spent in the INR
range of 1.6–1.9 (Figure 2).
Interacting medications
Overall, 79% of residents on warfarin therapy (83 resi-
dents) were prescribed at least one interacting drug during
the period of the chart review (mean no. interacting med-
ications = 1.8, range 1–6). The five most common drugs
were acetaminophen, citalopram, acetylsalicylic acid,
diltiazem and simvastatin (Table 1). To examine monitor-
ing practices, we further determined whether addition or
dose change of drugs known to interact with warfarin was
followed by INR measurement within seven days. There
were 72 instances of newly-initiated warfarin-interacting
medications or changes in dose. In 59 of 72 instances
(82%) the INR was checked within 7 days of the initiation
of the medication.
Residents receiving warfarin-interacting medications dur-
ing the period of the chart audit had a TTR of 53.0%, com-
pared with a TTR of 58.2% in the residents on no
interacting drugs (OR = 0.93, 95% CI, 0.88 to 0.97, P =
0.002). Residents with 2 or more interacting medications
had a lower TTR (50.8%) than those with only one inter-
acting medication (55.1%) (Table 2a).
Prescribing physicians
Twenty individual physicians were identified as warfarin
prescribers at the five facilities (prescribers-per-facility
range, 2–10). To increase the reliability of our observa-
tions, TTR was determined for only the ten physicians
with (1) three or more patients receiving warfarin and (2)
total patient-INR-days ≥ 700. We found significant differ-
ences in the achieved TTR between the physicians (range
Indications for warfarin Figure 1
Indications for warfarin. Indications for warfarin included as other: Sick sinus syndrome and peripheral vascular disease.
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45.9% to 63.3%, OR = 1.06, 95% CI, 1.00 to 1.13, p =
0.05, Table 2b).
Discussion
This study is the first to assess TTR in LTC residents on
warfarin in Canada. We found that the quality of antico-
agulant care was sub-optimal; overall, INR was in the ther-
apeutic range 54% of the time and was subtherapeutic
35% of the time. The majority of residents received at least
one warfarin-interacting drug. Eighty-two percent of times
an interacting drug was started, INR testing occurred
within one week, which compares favorably to monitor-
ing in a study in outpatients (INR testing within 14 days,
77% of the time) [14]. Despite monitoring, TTR was lower
in residents receiving warfarin-interacting medications.
The quality of anticoagulation also varied significantly
between physicians (TTR 45.9 to 63.3%).
The overall TTR result we obtained is comparable with
that reported in three previous studies (TTR range 40 to
51%) [15-17]. However, the values compare unfavorably
with an average TTR of 61% in studies in outpatients
receiving warfarin. [6]
The finding that patients in LTC facilities have suboptimal
INR control is surprising given the fact that many condi-
tions which predict poor control in the community (in
particular lack of compliance, failure to account for inter-
acting medications, and failure to undergo monitoring)
should be controlled in LTC. In fact each of these variables
was controlled in our study; patient compliance was
assured by central medication dispensing, monitored
administration and frequent monitoring [18,19]. In addi-
tion to frequent use of interacting drugs in a LTC setting,
other barriers to optimal INR control may include fre-
quent staff shift changes, communication failures regard-
ing dose adjustment and resident mental health issues.
Our study has several limitations including a limited sam-
ple size. The chart audit design did not allow us to track
the possible combined effect of interacting medications
and warfarin doses on INR results, limited our ability to
explore additional factors that may have contributed to
sub-optimal INR such as acute co-morbidities and varia-
bility in dietary vitamin K intake and also prevented mul-
tivariable analysis. In addition, we did not verify
administration of individual warfarin doses. Despite this
our results are important as we used rigorous methods to
review, in duplicate, clinical charts from a well character-
ized cohort of patients from a LTC facility. We carefully
calculated the TTR, and used rigorous statistical method-
ology to explore factors that may have contributed to
inadequate anticoagulant control.
Conclusion
Our study provides preliminary evidence of the high prev-
alence of co-prescription of warfarin and interacting med-
ications in LTC and the correlation with poorer INR
control. The area of co-prescription of warfarin and inter-
acting drugs has been inadequately studied – in the com-
munity and in LTC – and, to our knowledge, this study
represents the first study of its kind. As suggested by a
recent study in ambulatory care [20], a combined
approach of physician education and automated alerts
may be useful in decreasing co-prescription of interacting
drugs. If a warfarin-interacting drug was medically neces-
sary for a patient receiving oral anticoagulation, this
approach, combined with pharmacy monitoring, would
encourage prompt post-prescription INR monitoring.
Time-in-therapeutic range Figure 2
Time-in-therapeutic range. Over 28,555 resident-days, 
time spent in specific INR ranges.
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Table 1: Prevalence of interacting medications. Number 
(percentage) of residents prescribed each warfarin-interacting 
medication over the period of the chart audit.
Medication No. of Residents Prescribed (%)
Acetaminophen 42 (40%)
Citalopram 26 (25%)
Acetylsalicylic acid 17 (16%)
Diltiazem 12 (11%)
Simvastatin 10 (10%)
Levofloxacin 8 (8%)
Phenytoin 7 (7%)
Ciprofloxacin 5 (5%)
Sertraline 5 (5%)
Cotrimoxazole 3 (3%)
Metronidazole 3 (3%)
Clarithromycin 3 (3%)
Amiodarone 3 (3%)
Amoxicillin-clavulanate 2 (2%)
Miconazole 1 (1%)
Propranolol 1 (1%)
Fluvoxamine 1 (1%)
Medications not prescribed: erythromycin, fluconazole, fluvastatin, 
quinidine, ropinerole, celecoxib and entacapone.BMC Geriatrics 2008, 8:13 http://www.biomedcentral.com/1471-2318/8/13
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Our study was implemented after completion of a learn-
ing needs-assessment with the medical directors of the
five facilities. The results presented here have been shared
with all the directors of care who support a planned future
study assessing methods to improve TTR and drug-INR
monitoring in long-term care. This trial will compare a
previously validated decision-support tool [21] and auto-
mated interactions alerts with traditional physician man-
agement after academic detailing by a pharmacist on
appropriate target INR and interaction management.
Future studies should examine several variables simulta-
neously to determine which are most predictive of
improved TTR.
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